These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37607176)

  • 1. Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda.
    Amanya I; Muhoozi M; Aruhomukama D; Ssebagereka A; Mugambe R
    PLoS One; 2023; 18(8):e0277739. PubMed ID: 37607176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017-2019.
    Ssendikwanawa E; Juniour Nsubuga E; Lee S; Frances Zalwango J; Joan Bayowa R; Judith Ssemasaazi A; Ronald Muganga K; Adolphus C; Akunzirwe R; Nante Wangi R; Ronald Kasoma M; Kalyango JN; Karamagi C; Sekaggya-Wiltshire C
    J Clin Tuberc Other Mycobact Dis; 2023 May; 31():100349. PubMed ID: 37181458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Burden of Adverse Drug Reactions to Isoniazid Preventive Therapy in People Living With HIV at 3 Tertiary Hospitals in Uganda: Associated Factors.
    Nanyonga SM; Kitutu FE; Kalyango J; Frank M; Kiguba R
    J Acquir Immune Defic Syndr; 2022 Feb; 89(2):215-221. PubMed ID: 34693930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
    Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
    PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoniazid preventive therapy completion between July-September 2019: A comparison across HIV differentiated service delivery models in Uganda.
    Mugenyi L; Namuwenge PM; Ouma S; Bakashaba B; Nanfuka M; Zech J; Agaba C; Mijumbi Ojok A; Kaliba F; Bossa Kato J; Opito R; Miya Y; Katureebe C; Hirsch-Moverman Y
    PLoS One; 2024; 19(1):e0296239. PubMed ID: 38166009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in Uganda.
    Musaazi J; Sekaggya-Wiltshire C; Okoboi S; Zawedde-Muyanja S; Senkoro M; Kalema N; Kavuma P; Namuwenge PM; Manabe YC; Castelnuovo B; Kiragga A
    PLoS One; 2023; 18(2):e0268935. PubMed ID: 36821550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.
    Reddy MM; Thekkur P; Ramya N; Kamath PBT; Shastri SG; Kumar RBN; Chinnakali P; Nirgude AS; Rangaraju C; Somashekar N; Kumar AMV
    Glob Health Action; 2020; 13(1):1704540. PubMed ID: 31937200
    [No Abstract]   [Full Text] [Related]  

  • 10. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
    Kazibwe A; Oryokot B; Mugenyi L; Kagimu D; Oluka AI; Kato D; Ouma S; Tayebwakushaba E; Odoi C; Kakumba K; Opito R; Mafabi CG; Ochwo M; Nkabala R; Tusiimire W; Kateeba Tusiime A; Alinga SB; Miya Y; Etukoit MB; Biraro IA; Kirenga B
    PLoS One; 2022; 17(5):e0266285. PubMed ID: 35576223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
    Tram KH; Mwangwa F; Chamie G; Atukunda M; Owaraganise A; Ayieko J; Jain V; Clark TD; Kwarisiima D; Petersen ML; Kamya MR; Charlebois ED; Havlir DV; Marquez C;
    AIDS Care; 2020 Jan; 32(1):119-127. PubMed ID: 31181961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
    Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
    AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
    Ngugi SK; Muiruri P; Odero T; Gachuno O
    BMC Infect Dis; 2020 Apr; 20(1):294. PubMed ID: 32664847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019.
    Onyango DO; van der Sande MAB; Yuen CM; Mecha J; Matemo D; Oele E; Kinuthia J; John-Stewart G; LaCourse SM
    J Int AIDS Soc; 2022 Aug; 25(8):e25939. PubMed ID: 35927793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
    Semu M; Fenta TG; Medhin G; Assefa D
    BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.
    Otero L; Battaglioli T; Ríos J; De la Torre Z; Trocones N; Ordoñez C; Seas C; Van der Stuyft P
    Trop Med Int Health; 2020 Mar; 25(3):346-356. PubMed ID: 31758837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.